ATE156120T1 - Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen - Google Patents

Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE156120T1
ATE156120T1 AT92400295T AT92400295T ATE156120T1 AT E156120 T1 ATE156120 T1 AT E156120T1 AT 92400295 T AT92400295 T AT 92400295T AT 92400295 T AT92400295 T AT 92400295T AT E156120 T1 ATE156120 T1 AT E156120T1
Authority
AT
Austria
Prior art keywords
bizyclic
production
pharmaceutical compositions
compositions containing
nitrogen compounds
Prior art date
Application number
AT92400295T
Other languages
English (en)
Inventor
Francois Clemence
Michel Fortin
Jean-Luc Haesslein
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9101373A external-priority patent/FR2672595B1/fr
Priority claimed from FR9110434A external-priority patent/FR2680509B1/fr
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Application granted granted Critical
Publication of ATE156120T1 publication Critical patent/ATE156120T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
AT92400295T 1991-02-07 1992-02-05 Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen ATE156120T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9101373A FR2672595B1 (fr) 1991-02-07 1991-02-07 Nouveaux derives bicycliques azotes substitues par un radical benzyle, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments.
FR9110434A FR2680509B1 (fr) 1991-08-20 1991-08-20 Derives bicycliques azotes substitues par un radical benzyle, leur procede de preparation, les intermediaires obtenus, leur application a titre de medicaments et les compositions les renfermant .

Publications (1)

Publication Number Publication Date
ATE156120T1 true ATE156120T1 (de) 1997-08-15

Family

ID=26228496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92400295T ATE156120T1 (de) 1991-02-07 1992-02-05 Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen

Country Status (9)

Country Link
US (2) US5324839A (de)
EP (1) EP0498722B1 (de)
JP (1) JP3531944B2 (de)
AT (1) ATE156120T1 (de)
CA (1) CA2060771A1 (de)
DE (1) DE69221175T2 (de)
DK (1) DK0498722T3 (de)
ES (1) ES2104862T3 (de)
GR (1) GR3024413T3 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5719151A (en) * 1990-05-04 1998-02-17 Shall; Sydney Substituted benzene compounds
US6004979A (en) * 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
DK1156043T3 (da) * 1992-07-24 2004-03-01 Univ California Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer
EP0634175B1 (de) * 1993-07-15 2001-01-10 F. Hoffmann-La Roche Ag Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
US5852008A (en) * 1995-01-24 1998-12-22 The Regents Of The University Of California Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
CZ296163B6 (cs) * 1996-05-20 2006-01-11 Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
US6069151A (en) * 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
US6262070B1 (en) 1998-11-04 2001-07-17 Darwin Discovery Ltd. Heterocyclic compounds and their therapeutic use
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
WO2002012192A1 (en) 2000-08-09 2002-02-14 F. Hoffmann-La Roche Ag Quinolene derivatives as anti-inflammation agents
AU2001293817A1 (en) * 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
JP2004509875A (ja) * 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４−アミノキナゾリン
AU2002245709A1 (en) * 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
AR035791A1 (es) * 2001-03-23 2004-07-14 Bayer Corp Compuesto n,n-diheterociclico de amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y proceso para la preparacion del compuesto
US7829566B2 (en) * 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
AU2003202263A1 (en) * 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
CA2473510A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
US6943172B2 (en) * 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
WO2004035577A2 (en) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
GB0317631D0 (en) * 2003-07-28 2003-08-27 Btg Int Ltd Synthetic method
EP1742642B1 (de) * 2004-04-14 2008-10-15 Gilead Sciences, Inc. Phosphonatanaloga von hiv-integrasehemmerverbindungen
MX2007010572A (es) * 2005-03-01 2007-10-04 Wyeth Corp Compuestos de cinolina y su uso como moduladores de receptor x de higado.
JP2009502853A (ja) 2005-07-27 2009-01-29 エフ．ホフマン−ラ ロシュ アーゲー アリールオキシキノリン類及び５−ｈｔ６モジュレーターとしてのその使用
WO2007098214A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
AU2007223801A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
CA2772642C (en) 2009-09-03 2017-08-29 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG10201704095UA (en) 2012-04-24 2017-06-29 Vertex Pharma Dna-pk inhibitors
CN107200749B (zh) 2013-03-12 2019-09-03 沃泰克斯药物股份有限公司 Dna-pk抑制剂
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
EP3057953B1 (de) 2013-10-17 2018-08-15 Vertex Pharmaceuticals Incorporated Co-kristalle von (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)chinolin-4-carboxamid und deuterierten derivaten davon als dna-pk-hemmer
TW201815418A (zh) 2016-09-27 2018-05-01 Vertex Pharma 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1419789A (en) * 1972-08-02 1975-12-31 Pfizer 2-trifluoromethyl-4-quinolinols
US3936461A (en) 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2377400A2 (fr) 1977-01-18 1978-08-11 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
GB2143814A (en) 1983-07-29 1985-02-20 Showa Denko Kk Quinazolines
US4956371A (en) * 1989-09-19 1990-09-11 Euroceltique, S.A. Substituted isoquinolines and methods of using same

Also Published As

Publication number Publication date
CA2060771A1 (fr) 1992-08-08
ES2104862T3 (es) 1997-10-16
EP0498722B1 (de) 1997-07-30
US5478938A (en) 1995-12-26
US5324839A (en) 1994-06-28
DK0498722T3 (da) 1998-03-09
JP3531944B2 (ja) 2004-05-31
JPH04338378A (ja) 1992-11-25
GR3024413T3 (en) 1997-11-28
DE69221175D1 (de) 1997-09-04
EP0498722A1 (de) 1992-08-12
DE69221175T2 (de) 1998-01-15

Similar Documents

Publication Publication Date Title
ATE156120T1 (de) Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
ATE205832T1 (de) Stickstoff enthaltende bicyclische verbindungen, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende zusammensetzungen
ATE187964T1 (de) N-substituierte chinolinderivate, verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
IL103875A0 (en) Piperazinyl-and piperidinyl-cyclohexanol derivatives and pharmaceutical compositions containing the same
DE69219008D1 (de) Pyrimidinderivate, ihre Verfahren zur Herstellung, die erlangten Zwischenprodukte, ihre Anwendung als Heilmittel und diese enthaltende pharmazeutische Zusammensetzungen
ATE146186T1 (de) Trifluormethylketon peptid derivate mit hle- inhibierende aktivität, deren herstellung und pharmazeutischen zusammensetzungen
DE69214632T2 (de) 7-phenylethynyl-substituierte chromane und thiochromane mit retinoid-ähnlicher biologischer aktivität
CY1112062T1 (el) Παραγωγα πλευρομουτιλινης ως αντιμικροβιακα
ES2099186T3 (es) Nuevos inhibidores de elastasa activos por via oral.
DE69331888D1 (de) Bicyclische Pyridinderivate, Verfahren zu ihrer Herstellung, Zwischenprodukte, ihre Anwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
ES2112848T3 (es) Nuevos derivados de la n-acil-2,3-benzodiazepina.
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
ATE184274T1 (de) N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
ATE143938T1 (de) Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
ATE171177T1 (de) Benzimidazol-derivate, verfahren und zwischenprodukte zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
DE59003446D1 (de) 13-Brom und 13, 14-Dibrom-Ergoline, ihre Herstellung und Verwendung in Arzneimitteln.
ATE361775T1 (de) Körperpflegezusammensetzungen
DE69009211D1 (de) Derivate von Thiazolidin-4-carbonsäure, deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
AU598248B2 (en) Pharmaceutical sulphonamides of diarylmethanes
ES2144993T3 (es) Beta-dicetonas sustituidas y su uso en el tratamiento de enfermedades inflamatorias del intestino.
TNSN96168A1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent.
ATE55123T1 (de) Alkylcarbonsaeureamide von pyridinalkylaminen, ihre herstellung und ihre verwendung als arzneimittel.
AU6869996A (en) Use of esters of polyhydric alcohols to enhance the oral bioavailability of drug substances as well as novel esters and pharmaceutical compositions containing them
ATE130309T1 (de) 14alpha,16alpha-ethano- und 14alpha,16alpha- ethenoestratriene.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee